Published
At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Sia Daneshmand, MD, of University of Southern California, provides overviews and updates from three clinical trials involving cretostimogene for high-risk NMIBC: CORE-008, BOND-003, and PIVOT-006.
- Category
- Oncology
Be the first to comment
Up Next
-
12:02
AI-Powered Biomarkers and Precision Medicine in High-Risk NMIBC
-
12:41
Radical Prostatectomy Versus Radiotherapy in High-Risk Prostate Cancer
-
16:37
Expert Cancer Panel: High-risk MDS w/ excess blasts-2 diagnostics and management
-
05:29
2025 EAU Prostate Cancer Guidelines update: High risk, locally advanced and biochemical recurrence
-
08:22
BOND-003 With Dr. Mark D. Tyson: Cretostimogene for BCG-Unresponsive Bladder Cancer
-
04:54
Molecular Biomarkers and Risk Stratification in High-Risk Non-Muscle Invasive Bladder Cancer
-
08:33
The ABLE-32 Study: Nadofaragene Firadenovec for Intermediate-Risk NMIBC
-
04:08
Cretostimogene for Bladder Cancer: BOND-003 Study Ramifications
-
04:52
Genotype-Guided P2Y12 Inhibitor Monotherapy in High Bleeding Risk Patients
-
19:22
S. Katsianos | Case 2: PCI for high-risk/vulnerable plaque
-
09:07
Cardiology for Beginners: Basics of Heart Sounds and Murmurs (with examples)
-
13:45
How to Become a Cardiologist | Cardiac Electrophysiologist
-
04:14
V 00592 Cardiology Fellowship Video Dr Vranian V5
-
05:17
Cardiology Fellowship at SIU Medicine
-
04:15
Cardiology Fellowship Program at Danbury Hospital
-
05:49
Practice Question: Cardiology #1, USMLE Step 1, COMLEX Level 1
-
04:07
Dr. Muhammed Raza on advice for Fellows interested in Interventional Cardiology
-
07:36
Congenital Heart Disease – Cardiology | Lecturio
-
05:18
Cardiology Fellowship at IU School of Medicine
-
04:36
What are different types of Cardiology Tests | SPS Hospitals
